Antero Midstream Corporation logo AM - Antero Midstream Corporation

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 1
HOLD 12
SELL 4
STRONG
SELL
0
| PRICE TARGET: $24.00 DETAILS
HIGH: $24.00
LOW: $24.00
MEDIAN: $24.00
CONSENSUS: $24.00
UPSIDE: 6.62%

Stock News

Arrowstreet Capital Limited Partnership Makes New $4.44 Million Investment in Antero Midstream Corporation $AM

Arrowstreet Capital Limited Partnership Makes New $4.44 Million Investment in Antero Midstream Corporation $AM

Arrowstreet Capital Limited Partnership acquired a new stake in shares of Antero Midstream Corporation (NYSE: AM) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 194,808 shares of the pipeline company's stock, valued at approximately $4,442,000. Several other institutional investors have also

Aug 04, 2026 12:17 AM defenseworld.net
Antero Midstream Corporation $AM Shares Purchased by California State Teachers Retirement System

Antero Midstream Corporation $AM Shares Purchased by California State Teachers Retirement System

California State Teachers Retirement System raised its position in Antero Midstream Corporation (NYSE: AM) by 26.3% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 426,913 shares of the pipeline company's stock after purchasing an additional 88,900 shares during the period. California State Teachers Retirement

Aug 03, 2026 11:43 PM defenseworld.net
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidification and prolongation of Aramchol's IP protection Potential reduction in drug CoGs by ~50% Improvement in patients' convenience and compliance upon potential commercialization RAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001).

May 14, 2026 03:30 AM prnewswire.com

Price Targets